Onset: No acute "felt" effects on standard 50-200 mg doses. Pycnogenol is a slow-vascular-remodeling supplement, not a stimulant or sedative. Most users notice nothing day-of and nothing in week 1.

Effects at 4-8 weeks: Vascular and inflammatory effects emerge gradually. Reported by users with baseline issues:

• Reduced leg heaviness, less ankle swelling at end of long days
• Slightly improved cold-extremity perfusion (especially fingers, ears)
• Modest skin texture changes — some report less reactivity, fewer broken capillaries
• For users stacking with L-arginine: better morning erection quality, recovery from refractory period
• Less day-after stiffness post-hard training (anti-inflammatory + collagen support)
• Mild reduction in seasonal-allergy symptoms (taxifolin + NF-κB)

Effects at 12+ weeks: Where the real evidence base lives. BP reduction (only meaningful if baseline elevated). Sustained FMD improvement. Joint-pain reduction in OA patients.

What you won't feel: No mood lift, no cognitive sharpening, no energy push. The drug is mechanistically silent at the level of subjective awareness in healthy users. This is one of the harder-to-evaluate supplements precisely because the benefit shows up on biomarkers, not on the "do I feel different today" axis.

For a 20yo MMA athlete: Likely subjective baseline = nothing. Possible exceptions: faster bruise clearance (consistent with collagen/microcirculation support); reduced delayed-onset stiffness 24-48 hr post-spar (anti-inflammatory); slightly faster cold-water-immersion recovery. None of these are guaranteed and none will be obvious week 1.

Tolerance: None demonstrated. Pycnogenol's mechanism (eNOS upregulation, MMP inhibition, NF-κB suppression) is tissue-remodeling rather than receptor-saturating. Long-term studies (40+ week) show sustained effect without dose escalation.

Cycling: Not required. Continuous use is the clinical norm. Some users cycle off seasonally (e.g., 8 weeks on, 4 weeks off) on philosophical / "let the system recalibrate" grounds; there's no evidence-based reason to do so. If cycling, restart at the same effective dose — no titration needed.

Discontinuation: No rebound effect. Vascular benefits taper over weeks-months as eNOS expression returns to baseline. No autonomic withdrawal, no neuropsychiatric effects, no taper required.

Practical recommendation for Dylan: If trialing, continuous 100 mg/day for 8 weeks as an n=1 evaluation, then decide. No cycling necessary in either direction.

Synergistic with

• L-arginine 1-3 g/day — substrate-pairing synergy. Pycnogenol upregulates eNOS; arginine provides the substrate the enzyme converts to NO. Documented for ED (Prelox formulation, Stanislavov 2008). Also relevant for athletic vasodilation / pump-style training.
• L-citrulline 3-6 g/day — arginine precursor with better oral bioavailability; cleaner substitute for L-arginine. Same logic.
• CoQ10 100-200 mg/day — complementary mitochondrial-bioenergetics support. Common in CV stacks. Top community pairing (30 of 165 reports).
• Omega-3 (EPA+DHA) 1-3 g/day — top community pairing (52 of 165 reports). Independent and complementary mechanisms on endothelial function and inflammation.
• Vitamin C 500 mg-1 g/day — Pycnogenol recycles ascorbate radicals; pairing extends the antioxidant cycle.
• Cocoa flavanols (Cocoavia / Lavado) — overlapping mechanism, can be redundant; pair only if targeting very high antioxidant/NO load (athletic).
• Quercetin 500 mg/day — adjunct flavonoid for allergy / asthma indications. Mast-cell stabilization synergy.

Avoid stacking with

• Anticoagulants (warfarin, DOACs) — mild additive anti-platelet effect. Not a hard contraindication at typical doses but warrants discussion with prescribing physician if combined long-term.
• NSAIDs daily — additive GI / bleeding risk. Occasional NSAID use is fine; chronic NSAID + Pycnogenol is not.
• Other anti-platelet supplements (high-dose fish oil >3 g/day, vitamin E >800 IU, ginkgo, garlic extract) — pre-surgical bleeding risk compounds. Manage as a category, not per-supplement.
• Hypotensive medications without monitoring — additive BP effect. The Liu 2004 trial used this synergy to reduce nifedipine dose; in unmonitored setting it can cause symptomatic hypotension.

Redundant with (pick one)

• Grape seed extract (GSE) — overlapping OPC mechanism. The pragmatic budget alternative. Same family of procyanidins; lacks Pycnogenol's phenolic acid co-fraction but for general antioxidant/vascular use delivers ~80% of the benefit at ~20% the cost.
• High-dose cocoa flavanols (>500 mg/day) — same NO/endothelial mechanism.
• High-dose green tea catechins (EGCG-dominant) — overlapping antioxidant / NF-κB modulation; less endothelial-specific.

Neutral / safe co-administration

• All standard nootropics (modafinil, racetams, choline donors, theanine, rhodiola, ashwagandha) — no known interaction.
• BPC-157, TB-500, and most peptides — no known interaction; mechanism is non-overlapping.
• Creatine, beta-alanine, citrulline (already covered as synergy) — no negative interaction.
• All standard vitamins and minerals.

Pharmacokinetics: Pycnogenol's polyphenolic mixture is metabolized predominantly via gut-microbiota fermentation to phenolic-acid metabolites (caffeic acid, ferulic acid, valerolactones) and hepatic phase-II glucuronidation/sulfation. Limited CYP interaction in formal interaction studies. Some in-vitro evidence of mild CYP3A4 modulation; clinical relevance at standard doses appears low.

Clinically relevant interactions:

1. Anticoagulants (warfarin, DOACs) — additive bleeding risk

• Mild antiplatelet effect of Pycnogenol overlaps with these. Not contraindicated but warrants INR monitoring (warfarin) or shared decision (DOAC). Most common concern: pre-surgical period.

2. Antihypertensives — additive BP reduction

• Documented as a feature in Liu 2004 (nifedipine dose reduction). In uncontrolled settings or if user is not aware, symptomatic hypotension possible. Practical rule: if on antihypertensive therapy, monitor BP for first 4-6 weeks and consult prescriber if SBP <110.

3. Immunosuppressants / chemotherapy — Pycnogenol's antioxidant action is theoretically capable of attenuating ROS-dependent cytotoxic drugs (cisplatin, doxorubicin). Clinical evidence is limited and direction of effect unclear. Default: avoid during active chemotherapy unless cleared by oncologist.

4. NSAIDs / aspirin — additive GI and antiplatelet effect. Tolerable for occasional use; not for chronic high-dose combination.

5. Hormone therapy (HRT, oral contraceptives) — no documented interaction. Trials in menopausal symptoms used Pycnogenol alongside or without HRT without reported issue.

6. Diabetes medications — Pycnogenol modestly improves glucose regulation. Theoretical additive hypoglycemic effect with insulin/sulfonylureas. Monitor glucose during initiation.

7. ACE inhibitors / ARBs — additive BP and possible additive renal-protective effect (Cesarone 2010 renal flow study). No negative interaction reported.

8. Anesthesia (general / regional) — pre-surgical 2-week discontinuation as noted above.

Sparse data. Pycnogenol-specific pharmacogenetic studies do not exist in clinically actionable form as of 2026. General OPC/flavonoid metabolism is influenced by gut microbiota composition more than germline genetics. A few indirect considerations:

• eNOS polymorphisms (NOS3 Glu298Asp, T-786C) — Glu298Asp homozygotes have reduced baseline endothelial function and may respond more robustly to eNOS-upregulating interventions like Pycnogenol. Speculative; no formal Pycnogenol × NOS3 trials.
• Methylation (MTHFR C677T) — relevant to folate/homocysteine pathway, indirectly affects endothelial NO. Pycnogenol may have larger relative effect in MTHFR variants with elevated homocysteine. Speculative.
• Caffeic-acid metabolism (microbiota, COMT) — Pycnogenol's phenolic acid fraction is processed via methylation pathways. COMT Val/Val (fast methylators) may clear metabolites more rapidly. No clinical effect data.

For Dylan post-23andMe (June 2026): Worth pulling NOS3 and COMT genotypes from raw data via Promethease. If NOS3 Glu298Asp + COMT Met/Met, Pycnogenol may shift from "OPTIONAL-ADD" toward "WORTH-TRYING" on theoretical grounds. Not deterministic, but interpretable.

Pricing reality (May 2026):

• Pycnogenol 100 mg × 60 caps: ~$25-35 (Now Foods, Healthy Origins, Source Naturals — all Horphag-licensed)
• Pycnogenol 100 mg × 120 caps: ~$45-55 (better $/cap)
• Generic pine bark extract 100 mg × 100 caps: ~$8-15 (NOT Pycnogenol)
• Grape seed extract 200 mg × 100 caps: ~$8-12 (cleanest budget OPC alternative)

For Dylan: If trialing Pycnogenol specifically, Now Foods 100 mg × 120 caps (~$25-35) is the standard cost-effective Horphag-licensed product. Two-month trial supply for ~$35 is a reasonable n=1 experiment. If continuing long-term and budget matters, switch to grape seed extract 200 mg at $8-12/month for ~80% of the benefit (he loses the phenolic-acid co-fraction and the standardization guarantee but the core OPC vascular mechanism transfers).

Identification of legitimate Pycnogenol: Look for the registered trademark symbol (®) next to "Pycnogenol" on the label and "Horphag Research" or licensing-statement language in the supplement-facts panel. Generic "pine bark extract" with no Horphag attribution is, definitionally, not Pycnogenol.

Baseline (before starting)

• Resting BP (arm cuff, 3-day morning average) — Pycnogenol's most-documented quantitative effect. Useful as a measurable response signal.
• Lipid panel (LDL-C, HDL-C, triglycerides) — some evidence of mild improvement, especially in cardiometabolic populations.
• hs-CRP — anti-inflammatory effect should manifest if baseline elevated; near-floor in healthy young adults.
• Fasting glucose / HbA1c — modest improvement in diabetic / pre-diabetic users.
• Endothelial function (FMD) if accessible — gold standard but rarely available outside research / specialty settings.
• CBC, platelets — baseline before any anti-platelet supplement.
• Subjective signal baselines: bruise clearance time after typical training, post-spar joint stiffness 24-48 hr, cold-extremity perfusion, sleep, libido.

During use (Dylan-specific n=1)

• Week 2: any dizziness, GI upset, headache adjustment. Adjust dose if needed.
• Week 4: subjective signals — bruise clearance, recovery, joint stiffness. Compare to pre-trial baseline.
• Week 8: decision point. Repeat BP, repeat lipid + hs-CRP if originally on the margin, reassess subjective signals. Continue, drop, or substitute GSE.

Long-term

• Annual: standard CV panel (lipids, hs-CRP, BP). For Dylan, this overlaps with general annual bloodwork — no Pycnogenol-specific extra labs needed.
• Pre-surgery, pre-significant-bleeding-event: stop 14 days prior.